ProQR Therapeutics (NASDAQ:PRQR) Cut to "Sell" at StockNews.com

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Friday.

Several other research analysts also recently commented on PRQR. Chardan Capital reissued a "buy" rating and set a $2.50 price target on shares of ProQR Therapeutics in a research note on Friday. HC Wainwright reiterated a "buy" rating and issued a $5.00 target price on shares of ProQR Therapeutics in a research report on Friday. Finally, Citigroup upped their price target on shares of ProQR Therapeutics from $1.80 to $2.00 and gave the company a "buy" rating in a research report on Thursday, April 18th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $3.60.

ProQR Therapeutics Price Performance

NASDAQ:PRQR traded down $0.02 during midday trading on Friday, hitting $1.98. The company had a trading volume of 181,113 shares, compared to its average volume of 162,860. The company has a market capitalization of $161.09 million, a PE ratio of -5.08 and a beta of 0.30. The company has a quick ratio of 3.54, a current ratio of 3.54 and a debt-to-equity ratio of 0.10. ProQR Therapeutics has a 52-week low of $1.11 and a 52-week high of $3.29. The stock's fifty day moving average price is $2.13 and its 200-day moving average price is $1.95.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.08). The firm had revenue of $3.54 million during the quarter, compared to analysts' expectations of $27.88 million. ProQR Therapeutics had a negative return on equity of 56.71% and a negative net margin of 431.65%. As a group, research analysts expect that ProQR Therapeutics will post -0.37 earnings per share for the current year.

Institutional Investors Weigh In On ProQR Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new position in shares of ProQR Therapeutics in the first quarter valued at about $56,000. RFG Advisory LLC bought a new stake in shares of ProQR Therapeutics in the first quarter worth about $73,000. BNP Paribas Financial Markets grew its stake in shares of ProQR Therapeutics by 120.1% in the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company's stock worth $80,000 after purchasing an additional 19,100 shares during the last quarter. Finally, Monaco Asset Management SAM increased its holdings in ProQR Therapeutics by 58.9% during the 3rd quarter. Monaco Asset Management SAM now owns 377,517 shares of the biopharmaceutical company's stock valued at $491,000 after purchasing an additional 140,000 shares during the period. Hedge funds and other institutional investors own 32.65% of the company's stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.